Title: Investigator, Metro-Minnesota Community Oncology Research Consortium
Park Nicollet Frauenshuh Cancer Center title: Medical oncologist and hematologist and co-medical director for oncology research.
Joined the Institute: 2012
Education and training: MD, University of Minnesota Medical School; residency (internal medicine), University of Minnesota; chief residency, University of Minnesota (VA Hospital); fellowship (hematology/oncology), University of Minnesota; masters in clinical research, University of Minnesota.
Overview/research interests: In addition to his investigator-initiated research, Dr. Zylla is the principal investigator on numerous pharmaceutical clinical trials at Park Nicollet. Recently, he led a study assessing the impact of a synthetic cannabis product (Sativex) and continues to explore new ways to study the risks and benefits of medical cannabis through the Minnesota Medical Cannabis Program. Through his work with the Metro-Minnesota Community Oncology Research Consortium, he had the highest accrual of cancer patients in clinical trials in the Twin Cities in 2014. Dr. Zylla was also awarded the 2016 Association of Community Cancer Centers Innovation Award for “Establishing Personalized Pain Goals in Oncology Patients to Improve Care and Decrease Costs.” Dr. Zylla’s research focuses on how cancer pain and opioid utilization may impact survival in patients with advanced cancers. He leads projects focused on improving cancer pain and symptom management at Park Nicollet and collaborated with the American Society of Clinical Oncology on a project to improve the integration of palliative care into oncology practices. Dr. Zylla also serves on the Minnesota Community Measurement’s workgroup that develops quality measures for cancer symptom control using patient-reported outcomes.
Current research activities and funding:
- Implementation of electronic patient-reported outcomes to track cancer-related symptoms using Epic MyChart
- Impact of opioid use and mu-opioid receptor expression on survival in patients with newly diagnosed stage IV non-hematologic malignancies
- Medical cannabis use in stage IV cancers: a pilot and feasibility study
- Naloxegol as treatment option in patients with metastatic pancreas cancer
- Collaboration with Park Nicollet International Diabetes Center to improve diabetes management in patients receiving steroids with chemotherapy
- Co-investigator on the project “Development and Evaluation of a Patient-Centered Approach to Assess Quality of Care: Patient-Reported Outcomes-Based Performance Measures (PRO-PMs), which is funded by the Patient-Centered Outcomes Research Institute (principal investigator: Ethan Basch, MD)
- Site principal investigator on STARTRK-2: An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements
- Site principal investigator on GO29436: A Phase III, Open-Label, Randomized Study of Atezplizumab (MPDL32801A, Anti PD-L1 Antibody) in Combination with Carboplatin + Paclitaxel With or Without Bevacizumab Compared with Carboplatin Paclitaxel Bevaizumab in Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer
- Site principal investigator on Connect MDL and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry